Validity of cost-effectiveness models based on randomized clinical trials

December 8, 2009

Cost-effectiveness studies are widely used to guide prescribing policy in many countries, as part of health technology assessment programmes. However, a new study published this week in PLoS Medicine by Tjeerd-Pieter van Staa and colleagues suggests that cost-effectiveness analyses based on data from randomized controlled trials may not be realistic enough to accurately inform policy.

In the study the researchers (affiliated with the General Practice Research Database, and London School of Hygiene & Tropical Medicine in the UK, and Utrecht University in the Netherlands) specifically examine the relative cost-effectiveness of two commonly used groups of painkillers: selective cyclooxygenase-2 inhibitors (cox-2 inhibitors), versus conventional nonsteroidal anti-inflammatory drugs (NSAIDs). One type of cox-2 inhibitor has now been withdrawn from use, and recommendations regarding the use of others have changed as a result of data on cardiovascular harms associated with these drugs. The researchers collected data on the risk of upper gastrointestinal effects associated with use of either type of drug, and calculated the cost-effectiveness of the drugs in relation to these events using either data from large or from routine - using the UK General Practice Research Database.

These analyses showed that the average cost of preventing an upper gastrointestinal effect by switching NSAIDs for a cox-2 inhibitor was calculated at roughly US$104K, using the data from routine clinical practice. However, the cost effectiveness was calculated as around US$20K using randomized trial data.

The researchers suggest that in the specific scenario evaluated here, patients in the randomized trials experienced more gastrointestinal events than patients in routine practice, and that they used drugs differently - commonly involving higher daily doses - leading to a different estimate of cost-effectiveness. A more realistic assessment might have led to differences in prescribing guidelines, according to the authors. Tjeerd-Pieter van Staa says:

"Real-world questions on what to prescribe to whom should consider the varied group of patients in actual clinical practice rather than just using data from highly selective randomized trials that have narrow inclusion criteria."

However, one limitation of the study is that it involves an assessment of cost-effectiveness of two specific types of painkillers, and it isn't clear whether the observations will apply to cost-effectiveness for other drug classes.

More information: van Staa T-P, Leufkens HG, Zhang B, Smeeth L (2009) A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example. PLoS Med 6(12): e1000194. doi:10.1371/journal.pmed.1000194

Source: Public Library of Science (news : web)

Related Stories

Recommended for you

Make way for hemoglobin

August 18, 2017
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is ...

Bio-inspired materials give boost to regenerative medicine

August 18, 2017
What if one day, we could teach our bodies to self-heal like a lizard's tail, and make severe injury or disease no more threatening than a paper cut?

Are stem cells the link between bacteria and cancer?

August 17, 2017
Gastric carcinoma is one of the most common causes of cancer-related deaths, primarily because most patients present at an advanced stage of the disease. The main cause of this cancer is the bacterium Helicobacter pylori, ...

Two-step process leads to cell immortalization and cancer

August 17, 2017
A mutation that helps make cells immortal is critical to the development of a tumor, but new research at the University of California, Berkeley suggests that becoming immortal is a more complicated process than originally ...

Female mouse embryos actively remove male reproductive systems

August 17, 2017
A protein called COUP-TFII determines whether a mouse embryo develops a male reproductive tract, according to researchers at the National Institutes of Health and their colleagues at Baylor College of Medicine, Houston. The ...

New Pathology Atlas maps genes in cancer to accelerate progress in personalized medicine

August 17, 2017
A new Pathology Atlas is launched today with an analysis of all human genes in all major cancers showing the consequence of their corresponding protein levels for overall patient survival. The difference in expression patterns ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.